AMSTERDAM, Netherlands & SEATTLE--(BUSINESS WIRE)--Aug. 30, 2006--Targeted Genetics Corporation (Nasdaq:TGEN) announced that Nathan Clumeck, M.D., Ph.D., Head of the Department of Infectious Diseases, St. Pierre University Hospital in Brussels, Belgium, will present interim results today from a Phase I clinical trial of tgAAC09, an investigational HIV/AIDS vaccine candidate based on recombinant adeno-associated virus vector serotype 2 (AAV2). The trials for tgAAC09 are being conducted in collaboration with the International AIDS Vaccine Initiative (IAVI). The trial, enrolling healthy volunteers who are not infected with HIV, was conducted in Belgium and Germany, and is ongoing in India. Professor Clumeck is a principal investigator for this study and will present this data at the AIDS Vaccine 2006 Conference, taking place August 29 until September 1, 2006, in Amsterdam, Netherlands. A second clinical trial of tgAAC09 is ongoing in South Africa, Uganda and Zambia to evaluate a higher dose and to systematically evaluate the utility and optimal timing of boost vaccination.
